可用于某些医疗用途，美国或大幅降低大麻联邦管制级别

Group 1 - The U.S. federal government is considering a significant policy shift to lower the regulatory classification of cannabis from a Schedule I substance to a Schedule III substance, aligning it with common prescription painkillers [1] - Currently, cannabis is classified as a Schedule I substance, indicating high abuse potential and no accepted medical use, similar to heroin and LSD [1] - The proposed change would recognize cannabis as having a lower abuse risk and potential medical applications, similar to medications like Tylenol with codeine and certain steroids [1] Group 2 - Relevant A-share concept stocks include companies such as Chenguang Biotech and Fuan Pharmaceutical, which may benefit from the potential regulatory changes in cannabis [2]